Nando Mertineit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nando Mertineit has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Gerd Nöldge
Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital
9 shared publications - Frank Mosler
Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital
8 shared publications - Carlos Buitrago Tellez
Institut für Medizinische Radiologie (IMR) Bürgerspital Solothurn, Solothurn, Switzerland
3 shared publications - Keivan Daneshvar
Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Switzerland
3 shared publications - Pascal Kissling
Gefässzentrum Bürgerspital Solothurn, Solothurn, Switzerland
3 shared publications - Stefanie Nicole Garni
Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
2 shared publications
Latest Publications
- Open Access
- 30 July 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 10 (1) , 1-18
Splenic Artery Aneurysm Occlusion by Overlapping Gore® Viabahn® Endoprosthesis Devices
The first lienal artery aneurysm was discovered and described for the first time in 1770 by the Frenchman Beaussier during an autopsy. It was first visualised using X-rays in 1920 by the physicians Akbulut and Otan. The first surgical treatment of a splenic artery aneurysm was performed by sur-geons MacLeod and Maurice in 1940. The first minimally invasive endovascular therapies using coils, stents or a combination of the two devices for minimally invasive treatment of aneurysms of the lienal artery were reported in 1990, 1994 and 1995 (1,2,3). 63-year-old patient with a known aneurysmal arteriopathy of the thoracic aorta in the sense of an aortic dissection in coexistence with a 2.2 cm splenic artery aneurysm discovered by chance in the vascular surgery department of the Bürgerspital Solothurn. The interdisciplinary consensus primarily favoured vascular surgery or minimally invasive transcatheter treatment to eliminate the splenic artery aneurysm. The dissected thoracic aortic aneurysm detected in the pre-interventional CT of the thorax and abdomen, extending into the abdominal aorta, (Fig. 1) should only be treated with minimally invasive endovascular treatment using EVAR after stenting of the lienal artery aneurysm detected by CT (Fig. 9, 10, 11). A reverse therapeutic sequence would have allowed access to the lienal artery aneurysm only by fenestration of the EVAR. For the treatment of our patient's wide-neck aneurysm, the use of a Viabahn was chosen from the many known and proven occlusion materials as a significantly less invasive alternative to surgical treatment of the aneurysm by interdisciplinary consensus. Due to a technical complication during the deployment of the first vial, a two-stage angiographic therapeutic intervention was necessary.
- 30 July 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 10 (1) , 1-18
Open AccessSplenic Artery Aneurysm Occlusion by Overlapping Gore® Viabahn® Endoprosthesis Devices
The first lienal artery aneurysm was discovered and described for the first time in 1770 by the Frenchman Beaussier during an autopsy. It was first visualised using X-rays in 1920 by the physicians Akbulut and Otan. The first surgical treatment of a splenic artery aneurysm was performed by sur-geons MacLeod and Maurice in 1940. The first minimally invasive endovascular therapies using coils, stents or a combination of the two devices for minimally invasive treatment of aneurysms of the lienal artery were reported in 1990, 1994 and 1995 (1,2,3). 63-year-old patient with a known aneurysmal arteriopathy of the thoracic aorta in the sense of an aortic dissection in coexistence with a 2.2 cm splenic artery aneurysm discovered by chance in the vascular surgery department of the Bürgerspital Solothurn. The interdisciplinary consensus primarily favoured vascular surgery or minimally invasive transcatheter treatment to eliminate the splenic artery aneurysm. The dissected thoracic aortic aneurysm detected in the pre-interventional CT of the thorax and abdomen, extending into the abdominal aorta, (Fig. 1) should only be treated with minimally invasive endovascular treatment using EVAR after stenting of the lienal artery aneurysm detected by CT (Fig. 9, 10, 11). A reverse therapeutic sequence would have allowed access to the lienal artery aneurysm only by fenestration of the EVAR. For the treatment of our patient's wide-neck aneurysm, the use of a Viabahn was chosen from the many known and proven occlusion materials as a significantly less invasive alternative to surgical treatment of the aneurysm by interdisciplinary consensus. Due to a technical complication during the deployment of the first vial, a two-stage angiographic therapeutic intervention was necessary.
- Open Access
- 30 March 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 6 (1) , 10
Complex retrograde transarterial access and embolization of a giant internal iliac artery aneurysm after occlusion failure of Micro vascular plug (MVP) embolization and preceding EVAR in the distal ectatic Aorta and bilateral iliac artery aneurysms
The therapy of pelvic aneurysms is minimally invasive through interventional radiology using various devices and embolic agents: 1. By using a covered stent/prosthesis to maintain antegrade flow when a landing zone, i.e., a vascular segment angiographically present into which the stent can be placed to bridge the neck of the aneurysm, thereby interrupting aneurysm perfusion. 2. Through complete embolization of the aneurysm using embolic agents/coils. 3. As performed in our case, by covering the aneurysm (Img 14 A-C) with a covered stent /prosthesis, following prior embolization of the branching vessels using macroembolic agents. In cases where there is insufficient occlusion of the aneurysm with residual perfusion, secondary em- bolization becomes considerably more complex due to the occlusion of the anatomically antegrade access and the altered hemodynamics around the aneurysm causing retrograde collateralization. Through detailed analysis of CT angiography, even in static CT, retrograde circulation could be iden- tified, allowing for a minimally invasive secondary approach to the aneurysm without the need for general anesthesia and/or surgery. By completely eliminating the aneurysm, the risk of rupture in the elderly patient was minimally invasively eliminated. The treatment of this patient exemplifies the possibilities that embolization with a wide array of embolic agents and catheters offers in a hemo- dynamically very complex situation.
- 30 March 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 6 (1) , 10
Open AccessComplex retrograde transarterial access and embolization of a giant internal iliac artery aneurysm after occlusion failure of Micro vascular plug (MVP) embolization and preceding EVAR in the distal ectatic Aorta and bilateral iliac artery aneurysms
The therapy of pelvic aneurysms is minimally invasive through interventional radiology using various devices and embolic agents: 1. By using a covered stent/prosthesis to maintain antegrade flow when a landing zone, i.e., a vascular segment angiographically present into which the stent can be placed to bridge the neck of the aneurysm, thereby interrupting aneurysm perfusion. 2. Through complete embolization of the aneurysm using embolic agents/coils. 3. As performed in our case, by covering the aneurysm (Img 14 A-C) with a covered stent /prosthesis, following prior embolization of the branching vessels using macroembolic agents. In cases where there is insufficient occlusion of the aneurysm with residual perfusion, secondary em- bolization becomes considerably more complex due to the occlusion of the anatomically antegrade access and the altered hemodynamics around the aneurysm causing retrograde collateralization. Through detailed analysis of CT angiography, even in static CT, retrograde circulation could be iden- tified, allowing for a minimally invasive secondary approach to the aneurysm without the need for general anesthesia and/or surgery. By completely eliminating the aneurysm, the risk of rupture in the elderly patient was minimally invasively eliminated. The treatment of this patient exemplifies the possibilities that embolization with a wide array of embolic agents and catheters offers in a hemo- dynamically very complex situation.
- Open Access
- 30 March 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 6 (1) , 11-17
The Multiple Myeloma
The second most common hematologic malignancy is the clonal proliferation of neoplastic plasma cells within the bone marrow. There is the presence of monoclonal immunoglobulins in the serum and/or urine. This results in anemia, myelosuppression, bone destruction, and clinical consequences of paraproteinemia on kidney function and other organ systems. The disease manifests through the acronym CRAB (hypercalcemia, renal impairment, anemia, and bone lesions). Less frequent manifestations of multiple myeloma are of extramedullary localizations. Myeloma cells can become independent of the bone marrow microenvironment, circulate freely in the blood, and infiltrate organs. This results in a high-risk state characterized by increased proliferation, evasion of apoptosis, and treatment resistance. It can affect any area of tissue. Most commonly it involves the pleura, lymph nodes, chest wall, liver, skin/soft tissue, lungs, CNS, genitourinary system, breast and pancreas. In patients with confirmed multiple myeloma, the diagnosis of extramedullary involvement is typically established by the presence of pathological soft tissue masses using radiological methods such as computed tomography (CT) scan, positron emission tomography/CT (PET/CT), magnetic resonance imaging (MRI), or ultrasound, along with biopsy or physical examination. The molecular mechanisms underlying the development of extramedullary multiple myeloma (EMM) have not been fully defined. Various cytogenetic abnormalities are observed, and some studies have generated genomic sequencing profiles that distinguish EMM from classic multiple myeloma. While plasma cell leukemia (PCL) and central nervous system (CNS) EMM indicate a poor prognosis, outcomes for other manifestations can be highly heterogeneous. Sensitive imaging modalities including PET/CT and MRI (Fig.1) are integral components of diagnosis and response assessment. Patients with extramedullary multiple myeloma (EMM) have a clear survival disadvantage.
- 30 March 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 6 (1) , 11-17
Open AccessThe Multiple Myeloma
The second most common hematologic malignancy is the clonal proliferation of neoplastic plasma cells within the bone marrow. There is the presence of monoclonal immunoglobulins in the serum and/or urine. This results in anemia, myelosuppression, bone destruction, and clinical consequences of paraproteinemia on kidney function and other organ systems. The disease manifests through the acronym CRAB (hypercalcemia, renal impairment, anemia, and bone lesions). Less frequent manifestations of multiple myeloma are of extramedullary localizations. Myeloma cells can become independent of the bone marrow microenvironment, circulate freely in the blood, and infiltrate organs. This results in a high-risk state characterized by increased proliferation, evasion of apoptosis, and treatment resistance. It can affect any area of tissue. Most commonly it involves the pleura, lymph nodes, chest wall, liver, skin/soft tissue, lungs, CNS, genitourinary system, breast and pancreas. In patients with confirmed multiple myeloma, the diagnosis of extramedullary involvement is typically established by the presence of pathological soft tissue masses using radiological methods such as computed tomography (CT) scan, positron emission tomography/CT (PET/CT), magnetic resonance imaging (MRI), or ultrasound, along with biopsy or physical examination. The molecular mechanisms underlying the development of extramedullary multiple myeloma (EMM) have not been fully defined. Various cytogenetic abnormalities are observed, and some studies have generated genomic sequencing profiles that distinguish EMM from classic multiple myeloma. While plasma cell leukemia (PCL) and central nervous system (CNS) EMM indicate a poor prognosis, outcomes for other manifestations can be highly heterogeneous. Sensitive imaging modalities including PET/CT and MRI (Fig.1) are integral components of diagnosis and response assessment. Patients with extramedullary multiple myeloma (EMM) have a clear survival disadvantage.
- Open Access
- 24 February 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 5 (1) , 1-5
Regulatory Needs for Radiation Protection Devices based upon Artificial Intelligence
Artificial intelligence (AI) is increasingly employed in radiation protection, encompassing both medical devices and software. These technologies are integrated with AI throughout their manufacturing and application processes. This article underscores the imperative for comprehensive regulation in the utilization of AI. Decisions regarding AI application should not solely rest with manufacturers, medical professionals, or patients. Instead, an overarching "neutral" authority must be engaged to regulate, review, and enforce adherence to established protocols. The authors contend that relying on "self-regulation" within the free market, absent clear guidelines, proves to be inadequately effective and leads to patient's radiation protection safety issues.
- 24 February 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 5 (1) , 1-5
Open AccessRegulatory Needs for Radiation Protection Devices based upon Artificial Intelligence
Artificial intelligence (AI) is increasingly employed in radiation protection, encompassing both medical devices and software. These technologies are integrated with AI throughout their manufacturing and application processes. This article underscores the imperative for comprehensive regulation in the utilization of AI. Decisions regarding AI application should not solely rest with manufacturers, medical professionals, or patients. Instead, an overarching "neutral" authority must be engaged to regulate, review, and enforce adherence to established protocols. The authors contend that relying on "self-regulation" within the free market, absent clear guidelines, proves to be inadequately effective and leads to patient's radiation protection safety issues.
- Open Access
- 31 January 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 4 (1) , 1-9
Transarterial Embolization of Visceral Artery Aneurysms
The management of an aneurysm or pseudoaneurysm, including decisions regarding how, when, and with what method it should be treated, must always be determined through interdisciplinary consensus grounded in a thorough understanding of the existing literature. Consequently, today's preferred approach is embolization therapy or covered stenting. This method, performed in a minimally invasive manner, has been well-established due to its methodical low invasiveness and high effectiveness in achieving both technical and clinical success. It stands as a prominent choice among the available surgical and minimally invasive therapy options. The procedure, executed with advanced technology, utilizes the latest catheters and wires, coupled with expertise in various embolization methods. This comprehensive approach enables the treatment of acute bleeding in emergency cases, ensuring a nuanced and effective response (9-13).
- 31 January 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 4 (1) , 1-9
Open AccessTransarterial Embolization of Visceral Artery Aneurysms
The management of an aneurysm or pseudoaneurysm, including decisions regarding how, when, and with what method it should be treated, must always be determined through interdisciplinary consensus grounded in a thorough understanding of the existing literature. Consequently, today's preferred approach is embolization therapy or covered stenting. This method, performed in a minimally invasive manner, has been well-established due to its methodical low invasiveness and high effectiveness in achieving both technical and clinical success. It stands as a prominent choice among the available surgical and minimally invasive therapy options. The procedure, executed with advanced technology, utilizes the latest catheters and wires, coupled with expertise in various embolization methods. This comprehensive approach enables the treatment of acute bleeding in emergency cases, ensuring a nuanced and effective response (9-13).
- Open Access
- 31 January 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 4 (1) , 7
Comparison of CT and MR Imaging of Cystic Renal Masses by Using the Bosniak Classification System
Purpose: To compare the efficacy of computed tomography (CT) and magnetic resonance imaging (MRI) in evaluating cystic renal masses using the Bosniak classification system. Materials and Methods: Between January 2010 and December 2020, a total of 844 patients with suspected renal masses underwent total or partial nephrectomy at the Department of Urology, Heidelberg University Clinic. Among them, 123 patients presented with cystic renal masses. Out of this cohort, 15 patients underwent preoperative examinations using both MRI and CT within a 6-week timeframe. These examinations were retrospectively analyzed by two radiologists employing the Bosniak classification system. Each lesion was assessed based on CT images for lesion localization, volume, number, and thickness of septa/wall, calcification, presence of enhancing soft-tissue components, and lesion density. Pathologic correlation was available for all lesions. Results: Out of the 844 patients, 15 underwent both CT and MR imaging examinations (male-to-female ratio: 2.75, age range: 43-75 years; mean age: 60.5 years). Based on CT images, there were one category I, one category II, three category IIF, three category III, and seven category IV lesions. Findings based on CT and MR images were concordant in eleven (73.3%) renal lesions, while in 4 (26.7%) masses, differences were observed. In three (20%) cases, MR imaging revealed more septa/wall than CT, resulting in an upgrade of the classification at MR imaging. In one (6.7%) lesion, MR imaging showed no wall and/or septa thickness compared with CT, leading to a classification downgrade. MR imaging results led to a cyst classification upgrade in three masses (from category II to III, n=1; IIF to III, n=2) and downgrade in one lesion (from category IIF to II). Pathologically, 11 lesions (73.3%) were malignant (9 Cystic Clear cell carcinoma and 2 papillary renal cell carcinoma), while 4 lesions were renal cysts without malignancy. Conclusion: The majority of findings from both CT and MR imaging were similar in suspected cystic renal masses. MR imaging demonstrated additional septa/wall or septa/wall thickening, potentially upgrading lesions from borderline category IIF to III compared to CT. This distinction may contribute to improved case management.
- 31 January 2024
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 4 (1) , 7
Open AccessComparison of CT and MR Imaging of Cystic Renal Masses by Using the Bosniak Classification System
Purpose: To compare the efficacy of computed tomography (CT) and magnetic resonance imaging (MRI) in evaluating cystic renal masses using the Bosniak classification system. Materials and Methods: Between January 2010 and December 2020, a total of 844 patients with suspected renal masses underwent total or partial nephrectomy at the Department of Urology, Heidelberg University Clinic. Among them, 123 patients presented with cystic renal masses. Out of this cohort, 15 patients underwent preoperative examinations using both MRI and CT within a 6-week timeframe. These examinations were retrospectively analyzed by two radiologists employing the Bosniak classification system. Each lesion was assessed based on CT images for lesion localization, volume, number, and thickness of septa/wall, calcification, presence of enhancing soft-tissue components, and lesion density. Pathologic correlation was available for all lesions. Results: Out of the 844 patients, 15 underwent both CT and MR imaging examinations (male-to-female ratio: 2.75, age range: 43-75 years; mean age: 60.5 years). Based on CT images, there were one category I, one category II, three category IIF, three category III, and seven category IV lesions. Findings based on CT and MR images were concordant in eleven (73.3%) renal lesions, while in 4 (26.7%) masses, differences were observed. In three (20%) cases, MR imaging revealed more septa/wall than CT, resulting in an upgrade of the classification at MR imaging. In one (6.7%) lesion, MR imaging showed no wall and/or septa thickness compared with CT, leading to a classification downgrade. MR imaging results led to a cyst classification upgrade in three masses (from category II to III, n=1; IIF to III, n=2) and downgrade in one lesion (from category IIF to II). Pathologically, 11 lesions (73.3%) were malignant (9 Cystic Clear cell carcinoma and 2 papillary renal cell carcinoma), while 4 lesions were renal cysts without malignancy. Conclusion: The majority of findings from both CT and MR imaging were similar in suspected cystic renal masses. MR imaging demonstrated additional septa/wall or septa/wall thickening, potentially upgrading lesions from borderline category IIF to III compared to CT. This distinction may contribute to improved case management.
- Open Access
- 30 September 2023
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 3 (1) , 11-17
Uncommon Cause of Recurrent Pneumonias
A patient who presented with sudden shortness of breath, stridor, and recurrent laryngeal nerve paralysis was diagnosed with a tracheal diverticulum. The diagnosis was established through CT scans and confirmed via endoscopy. Distinctive CT findings revealed an air-filled, tubular structure located behind and slightly to the right lateral of the trachea, which communicated with it. Endoscopy demonstrated a narrow-mouthed diverticulum originating from the posterior right wall of the trachea, approximately 8 cm below the level of the true vocal cords. Successful medical treatment was administered, and the patient experienced an uncomplicated recovery.
- 30 September 2023
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 3 (1) , 11-17
Open AccessUncommon Cause of Recurrent Pneumonias
A patient who presented with sudden shortness of breath, stridor, and recurrent laryngeal nerve paralysis was diagnosed with a tracheal diverticulum. The diagnosis was established through CT scans and confirmed via endoscopy. Distinctive CT findings revealed an air-filled, tubular structure located behind and slightly to the right lateral of the trachea, which communicated with it. Endoscopy demonstrated a narrow-mouthed diverticulum originating from the posterior right wall of the trachea, approximately 8 cm below the level of the true vocal cords. Successful medical treatment was administered, and the patient experienced an uncomplicated recovery.
- Open Access
- 1 June 2023
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 1 (1) , 2-11
Diagnostic lymphangiography with therapeutic effect: Since more than 70 years Lipiodol is used as an off-label standard of care for chylothorax - why not convert to on-label use?
Purpose: The use of Lipiodol as a diagnostic agent and off-label therapeutic agent has been investigated in well over 395 publications listed in Pubmed under the key words: lymphangiography and chylothorax in the time period between 1921-2021. While Lipiodol® ultra-fluid has been approved for use as a diagnostic agent in most countries, it can only be used off-label as a therapeutic agent for chylothorax, cholascos, and lymphatic leaks and fistulas. The therapeutic effects in chylothorax and the question why Lipiodol® ultra-fluid is still not approved for on-label use in the treatment of chylothorax are reviewed. Background: Lipiodol was synthesized as iodized poppy seed oil by the French pharmacist Marcel Guerbet and first described by him in 1901. Over the past 12 decades, it has proven to be a reliable and versatile clinical theranostic agent. Lipiodol® ultra-fluid has been used (a) as a diagnostic contrast agent alone in the clarification and (b) so far only in off-label use as a therapeutic agent for chylothorax or cholascos, e.g. in cases of postoperative lymph leakages. Lipiodol® ultra-fluid has, to our knowledge, only very limited approvals as a therapeutic agent, in Switzerland only for transarterial chemo-embolization (TACE) for liver cancer. For decades and in numerous countries, Lipiodol® ultra-fluid has been in use as first-line treatment of chylothorax, cholascos, lymphatic leakage or lymphatic fistulae, avoiding additional interventions or surgery. This review aims to assess in which countries Lipiodol® ultra-fluid is approved (a) as a primary diagnostic tool and (b) as a first line therapeutic agent. This review wants to reassess why the general therapeutic approval still lacks, and what could be done to achieve it.
- 1 June 2023
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 1 (1) , 2-11
Open AccessDiagnostic lymphangiography with therapeutic effect: Since more than 70 years Lipiodol is used as an off-label standard of care for chylothorax - why not convert to on-label use?
Purpose: The use of Lipiodol as a diagnostic agent and off-label therapeutic agent has been investigated in well over 395 publications listed in Pubmed under the key words: lymphangiography and chylothorax in the time period between 1921-2021. While Lipiodol® ultra-fluid has been approved for use as a diagnostic agent in most countries, it can only be used off-label as a therapeutic agent for chylothorax, cholascos, and lymphatic leaks and fistulas. The therapeutic effects in chylothorax and the question why Lipiodol® ultra-fluid is still not approved for on-label use in the treatment of chylothorax are reviewed. Background: Lipiodol was synthesized as iodized poppy seed oil by the French pharmacist Marcel Guerbet and first described by him in 1901. Over the past 12 decades, it has proven to be a reliable and versatile clinical theranostic agent. Lipiodol® ultra-fluid has been used (a) as a diagnostic contrast agent alone in the clarification and (b) so far only in off-label use as a therapeutic agent for chylothorax or cholascos, e.g. in cases of postoperative lymph leakages. Lipiodol® ultra-fluid has, to our knowledge, only very limited approvals as a therapeutic agent, in Switzerland only for transarterial chemo-embolization (TACE) for liver cancer. For decades and in numerous countries, Lipiodol® ultra-fluid has been in use as first-line treatment of chylothorax, cholascos, lymphatic leakage or lymphatic fistulae, avoiding additional interventions or surgery. This review aims to assess in which countries Lipiodol® ultra-fluid is approved (a) as a primary diagnostic tool and (b) as a first line therapeutic agent. This review wants to reassess why the general therapeutic approval still lacks, and what could be done to achieve it.
- Open Access
- 1 June 2023
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 1 (1) , 12-18
Osteoid Osteoma – Synopsis of clinical, radiological, and therapeutical relevance of this rare entity
Characteristic of the osteoid osteoma is the so-called nidus enclosed in the tumor and produces a typical picture on X-ray. Since most physicians have little experience with the clinical picture of osteoid osteoma, this is an important reason for the often-long anamnesis time for osteoid osteoma (OO). The period of formation of OO includes the phase of strongest bone growth in childhood and adolescence. The most characteristic clinical symptom is nocturnal attacks of pain around the tumor, which occur independently of preceding physical activity and respond strikingly well to non-steroidal anti-inflammatory drugs (aspirin test). OO most frequently affects the long tubular bones of the lower extremities. Fifty percent of OO are found in the femur and tibia preferentially occurring in the corticalis of metaphysis and diaphysis. This is followed by the long tubular bones of the upper extremity and the short tubular bones. However, any other bone can also be affected. Differentially, osteoblastoma or osteosarcoma must be considered first and foremost. Most widely accepted therapy options are open surgery with en-bloc resection of the tumor, excochleation,minimally invasive percutaneous CT-guided radio or laser ablation. A conservative management by pharmaceutical pain therapy should be reserved for cases in which surgery must be refused either because of the precarious position of the nidus or because the patient's general condition does not permit it, or the patient does not consent to surgical interventions.
- 1 June 2023
- Published by SJORANM GmbH in Swiss Journal of Radiology and Nuclear Medicine
- Vol. 1 (1) , 12-18
Open AccessOsteoid Osteoma – Synopsis of clinical, radiological, and therapeutical relevance of this rare entity
Characteristic of the osteoid osteoma is the so-called nidus enclosed in the tumor and produces a typical picture on X-ray. Since most physicians have little experience with the clinical picture of osteoid osteoma, this is an important reason for the often-long anamnesis time for osteoid osteoma (OO). The period of formation of OO includes the phase of strongest bone growth in childhood and adolescence. The most characteristic clinical symptom is nocturnal attacks of pain around the tumor, which occur independently of preceding physical activity and respond strikingly well to non-steroidal anti-inflammatory drugs (aspirin test). OO most frequently affects the long tubular bones of the lower extremities. Fifty percent of OO are found in the femur and tibia preferentially occurring in the corticalis of metaphysis and diaphysis. This is followed by the long tubular bones of the upper extremity and the short tubular bones. However, any other bone can also be affected. Differentially, osteoblastoma or osteosarcoma must be considered first and foremost. Most widely accepted therapy options are open surgery with en-bloc resection of the tumor, excochleation,minimally invasive percutaneous CT-guided radio or laser ablation. A conservative management by pharmaceutical pain therapy should be reserved for cases in which surgery must be refused either because of the precarious position of the nidus or because the patient's general condition does not permit it, or the patient does not consent to surgical interventions.
- Open Access
- 12 May 2017
- Published by Springer Nature in Diagnostic Pathology
- Vol. 12 (1) , 39
Intestinal differentiated mucinous adenocarcinoma of the endometrium with sporadic MSI high status: a case report
Intestinal differentiation of primary mucinous adenocarcinoma of the uterine corpus is exceedingly rare in comparison to the approximately 25% rate in endocervical and ovarian mucinous carcinoma. Additionally, little is known about the related genetic and epigenetic alterations, even though large-scale molecular characterisation of the different types of endometrial cancer took place in the TCGA project along the entities defined by the recent WHO classification. We present a 62-year-old patient harbouring a primary mucinous carcinoma of the uterine corpus with a morphological resemblance to mucinous colorectal adenocarcinoma. The intestinal differentiation was substantiated by CDX2 and CK20 positivity in the absence of PAX8, p16, WT1, p53, ER, PgR, AFP, SALL4 and Glypican3. A high MSI status with MLH1 hypermethylation was revealed by molecular testing. Intestinal differentiation of mucinous adenocarcinoma of the endometrium is a unique observation. Besides morphology, it obviously can share molecular features of sporadic MSI colorectal cancers. It can be speculated that either CDX2 positive morula formation or intestinal metaplasia of the endometrium as rare conditions might be the origin of carcinogenesis for this type II endometrial cancer. Both conditions were not detectable in this case. Of note, categorising endometrial cancers in genetic subgroups like MSI high cancers alone might lead to the integration of likewise morphologically different tumours like the case presented here with intestinal differentiation. Hence, careful genotype-phenotype correlations are warranted for studies of mucinous adenocarcinoma of the endometrium.
- 12 May 2017
- Published by Springer Nature in Diagnostic Pathology
- Vol. 12 (1) , 39
Open AccessIntestinal differentiated mucinous adenocarcinoma of the endometrium with sporadic MSI high status: a case report
Intestinal differentiation of primary mucinous adenocarcinoma of the uterine corpus is exceedingly rare in comparison to the approximately 25% rate in endocervical and ovarian mucinous carcinoma. Additionally, little is known about the related genetic and epigenetic alterations, even though large-scale molecular characterisation of the different types of endometrial cancer took place in the TCGA project along the entities defined by the recent WHO classification. We present a 62-year-old patient harbouring a primary mucinous carcinoma of the uterine corpus with a morphological resemblance to mucinous colorectal adenocarcinoma. The intestinal differentiation was substantiated by CDX2 and CK20 positivity in the absence of PAX8, p16, WT1, p53, ER, PgR, AFP, SALL4 and Glypican3. A high MSI status with MLH1 hypermethylation was revealed by molecular testing. Intestinal differentiation of mucinous adenocarcinoma of the endometrium is a unique observation. Besides morphology, it obviously can share molecular features of sporadic MSI colorectal cancers. It can be speculated that either CDX2 positive morula formation or intestinal metaplasia of the endometrium as rare conditions might be the origin of carcinogenesis for this type II endometrial cancer. Both conditions were not detectable in this case. Of note, categorising endometrial cancers in genetic subgroups like MSI high cancers alone might lead to the integration of likewise morphologically different tumours like the case presented here with intestinal differentiation. Hence, careful genotype-phenotype correlations are warranted for studies of mucinous adenocarcinoma of the endometrium.